Does process excellence handcuff drug development?

Drug Discovery Today

Volumn 16, Issue 9-10, 2011, Pages 377-381

  Koenig, Jochen ^a  

^a IDS Scheer Consulting   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

COOPERATION; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; INFORMATION TECHNOLOGY; PATENT; PROCESS DESIGN; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; QUALITY CONTROL; REVIEW; STANDARDIZATION;

EID: 79956035553     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.02.010     Document Type: Short Survey

References (22)

1. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
2. Pharmaceutical Research and Manufacturers of America Pharmaceutical Industry Profile 2010 2010 PhRMA
3. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. J. Walker M&A activity in 2009 Nat. Rev. Drug Discov. 9 2009 95
5. P. Branthwaite The shrinking of the knowledge base - what is the impact of this on the speed and security of drug development? Drug Discov. Today 15 2010 1 2
6. G. Miller Spare pharma the dot-com cleaver FiercePharma Manufacturing 2010 [last accessed 2011-03-02] http://www.fiercepharmamanufacturing.com/story/ spare-pharma-dot-com-cleaver/2010-09-13
7. EFPIA The Innovative Medicines Initiative (IMI) Strategic Research Agenda - Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society (Version 2.0) 2006 [last accessed 2011-03-02] http://www.imi-europe.org/ Lists/IMIPublicationDocuments/Strategic%20Research%20Agenda%20(Version%202).pdf
8. US Food and Drug Administration Challenge and opportunity on the critical path to new medical products Critical Path Opportunities Report 2006 [last accessed 2011-03-02] http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf
9. J.S. Ozer A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function Nat. Biotechnol. 28 2010 486 494
10. F.D. Sistare Towards consensus practices to qualify safety biomarkers for use in early drug development Nat. Biotechnol. 28 2010 446 454
11. F. Dieterle Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat. Biotechnol. 28 2010 455 462
12. S. Usdin, and D. Flores Regulatory innovation BioCentury 18 2010 A1 A13
13. B. Jones As Science Evolves, How Can Science Policy? NBER Working Paper No. 16002 2010 [last accessed 2011-03-02] http://papers.nber.org/papers/w16002
14. S. Carney How can we avoid the productivity gap? Drug Discov. Today 10 2005 1011 1013 (Pubitemid 41074134)
15. S.W. Carleysmith Implementing Lean Sigma in pharmaceutical research and development: a review by practitioners R&D Management 39 2009 95 106
16. C. Johnstone Creativity, innovation and Lean Sigma: a controversial combination? Drug Discov. Today 16 2010 50 57
17. S. Andersson Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
18. D. Lowe Six Sigma in drug discovery? Part one The Pipeline Blog Entry 2010 [last accessed 2011-03-02] http://pipeline.corante.com/archives/2010/09/16/ six-sigma-in-drug-discovery-part-one.php
19. T. Blickle Process Intelligence For Dummies 2010 Wiley Publishing Inc. ISBN 978-0-470-87620-6
20. W. Keighley, and A. Sewing New working paradigms in research laboratories Drug Discov. Today 14 2009 625 629
21. K. Davies.The Broad's approach to genome sequencing (part I) BioIT World 2010 [last accessed 2011-03-02] http://www.bio-itworld.com/news/09/16/10/Broad- approach-genome-sequencing-partI.html
22. A.S. Rathore, and H. Winkle Quality by design for biopharmaceuticals Nat. Biotechnol. 27 2009 26 34